Review Articles
The new oral antiviral agents for COVID-19
Authors:
S.L. Seneviratne ,
Royal Free Hospital and University College London, UK; Consultant Physician Nawaloka Hospital Research and Education Foundation, Nawaloka Hospitals PLC, LK
About S.L.
Professor in Immunology, Institute of Immunity and Transplantation
C. Dalugama,
Faculty of Medicine, University of Peradeniya, LK
About C.
Consultant Physician (Acting) and lecturer in medicine, Department of Medicine
P. Madanayake,
John Radcliffe Hospital Oxford, GB
About P.
Specialist Registrar in Acute Medicine, Department of Acute Medicine
B. Samaraweera,
Liberty Publishers Private Limited, LK
About B.
Research Fellow
J. Kariyawasam,
Sir John Kotalawala Defence University, Ratmalana, LK
About J.
Scientist, Biomedical Laboratory 2
V. Abeysuriya
Royal Free Hospital and University College London, GB
About V.
Medical Officer, Institute of Immunity and Transplantation
Abstract
Coronavirus Disease-2019 (COVID-19), has so far affected more than 275 million individuals globally and caused over 5.3 million deaths. With an effective vaccine, disease and infection could be prevented, whereas with antivirals and monoclonal antibodies, disease progression could be mitigated. In recent months, there has been much interest in evaluating the use of oral antivirals, in those having mild disease and associated risk factors for disease progression (such as multiple comorbidities), in view of preventing severe COVID-19. Our review discusses the known properties and identified effectiveness of three oral antiviral drugs (Molnupiravir, Paxlovid and AT-527) for COVID-19 (as at end of December 2021) and explores their potential role in mitigating the ill effects of the on-going COVID-19 pandemic.
How to Cite:
Seneviratne SL, Dalugama C, Madanayake P, Samaraweera B, Kariyawasam J, Abeysuriya V. The new oral antiviral agents for COVID-19. Asian Journal of Internal Medicine. 2022;1(1):50–9. DOI: http://doi.org/10.4038/ajim.v1i1.31
Published on
31 Jan 2022.
Peer Reviewed
Downloads
